Name | Vitamin D2, 1a-Hydroxy- |
Synonyms | 1ALPHA-OH-D2 Doxercalciferol Vitamin D2, 1a-Hydroxy- 1-hydroxyergocalciferol 1-alpha-hydroxyvitamind2 VITAMIN D2, 1ALPHA-HYDROXY- 1alpha-hydroxyergocalciferol 1-alpha-hydroxyergocalciferol 1α-hydroxyergocalciferol (Ercalcidol) (1S,3R,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol (1S,3R,5Z,7E,14xi,22E)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol 7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5z,7e,22e)-10-secoergosta-5 (2S,4S,5E,7E,17beta)-1-methylidene-17-[(1R,2E)-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-2,4-diol |
CAS | 54573-75-0 |
InChI | InChI=1/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26?,27-,28+/m0/s1 |
Molecular Formula | C28H44O2 |
Molar Mass | 412.65 |
Density | 1.01±0.1 g/cm3(Predicted) |
Melting Point | 138-140°C |
Boling Point | 538.7±50.0 °C(Predicted) |
Flash Point | 223.996°C |
Solubility | DMSO: >10mg/mL |
Vapor Presure | 0mmHg at 25°C |
Appearance | White crystalline solid |
Color | White to Almost white |
pKa | 14.43±0.40(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Refractive Index | 1.541 |
MDL | MFCD00871065 |
In vivo study | In nephrectomized-treated mice, Doxercalciferol(100 or 300 Pico/g) normalized serum calcium and parathyroid hormone (PTH) levels. In nephrectomy-treated mice, Doxercalciferol(300 Pico/g) significantly reduced osteitis fibrosa. In high-salt (HS) fed mice, Doxercalciferol caused a significant decrease in cardiac hypertrophy and improved cardiac function. In high-salt (HS)-fed mice, Doxercalciferol caused significant reductions in plasma brain natriuretic peptide (BNP) levels and tissue atrial natriuretic factor (ANF)mRNA levels. Doxercalciferol also significantly reduced levels of the protein kinase C- Alpha, suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. In diet-induced obese (DIO) mice, Doxercalciferol reduced proteinuria, podocyte damage, mesangial distension, and accumulation of extracellular matrix proteins. In DIO mice, Doxercalciferol also reduced macrophage infiltration, oxidative stress, pro-inflammatory cytokines, and pro-fibrotic growth factors. In DIO mice, Doxercalciferol also prevented the activation of the renin-angiotensin-aldosterone system, including the angiotensin type -1 receptor and the mineralocorticoid receptor. In mice, the combination of Doxercalciferol and Losartan was most effective in preventing albuminuria, restoring glomerular filtration barrier architecture, and significantly reducing glomerulosclerosis in a dose-dependent manner. The combination of Doxercalciferol and Losartan prevents morphological and molecular changes in the diabetic kidney of mice. |
Hazard Symbols | T+ - Very toxic |
Risk Codes | 28 - Very Toxic if swallowed |
Safety Description | S28 - After contact with skin, wash immediately with plenty of soap-suds. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1 / PGIII |
WGK Germany | 3 |
RTECS | VS2950000 |
HS Code | 2936299055 |
Toxicity | LD50 orally in rats: 3.5-6.5 mg/kg (Sjden) |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
Biological activity | Doxercalciferol (1α-hydroxyvitamin D2) is a synthetic vitamin D analog. |
target | Vitamin d receptor |